GoodRx (NASDAQ:GDRX) Major Shareholder Sells $1,574,351.68 in Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 447,259 shares of the company’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $3.52, for a total transaction of $1,574,351.68. Following the completion of the transaction, the insider owned 913,592 shares of the company’s stock, valued at $3,215,843.84. This represents a 32.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The stock was sold at an average price of $3.50, for a total value of $961,509.50.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The shares were sold at an average price of $3.53, for a total value of $1,666,071.75.

GoodRx Price Performance

GoodRx stock opened at $3.45 on Monday. The company has a market capitalization of $1.18 billion, a P/E ratio of 86.27, a PEG ratio of 1.72 and a beta of 1.60. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.38 and a current ratio of 1.38. GoodRx Holdings, Inc. has a fifty-two week low of $1.77 and a fifty-two week high of $5.81. The stock has a 50-day simple moving average of $3.13 and a 200-day simple moving average of $2.63.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.08. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The firm had revenue of $200.41 million for the quarter, compared to the consensus estimate of $193.23 million. During the same quarter last year, the business posted $0.09 EPS. The firm’s quarterly revenue was down 1.3% compared to the same quarter last year. Equities research analysts expect that GoodRx Holdings, Inc. will post 0.16 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its holdings in GoodRx by 124.4% in the 1st quarter. AQR Capital Management LLC now owns 282,320 shares of the company’s stock valued at $1,245,000 after purchasing an additional 156,482 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of GoodRx by 7.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 783,378 shares of the company’s stock valued at $3,455,000 after buying an additional 54,783 shares during the period. Jane Street Group LLC acquired a new stake in shares of GoodRx in the 1st quarter valued at approximately $370,000. Creative Planning purchased a new stake in shares of GoodRx in the second quarter valued at approximately $93,000. Finally, Cetera Investment Advisers purchased a new stake in shares of GoodRx in the second quarter valued at approximately $50,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Barclays lifted their target price on shares of GoodRx from $3.00 to $4.00 and gave the company an “underweight” rating in a report on Thursday. UBS Group increased their price target on shares of GoodRx from $2.50 to $3.75 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. The Goldman Sachs Group reissued a “neutral” rating and set a $4.00 price objective on shares of GoodRx in a research report on Friday, August 7th. Leerink Partners set a $5.00 price objective on shares of GoodRx in a research note on Thursday, August 6th. Finally, Weiss Ratings raised shares of GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, August 7th. Four analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $4.23.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.